Torbjörn Tomson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Torbjörn Tomson has a total of 551 co-authors. Here are the top co-authors by number of shared publications:
Dina Battino
Epilepsy Center, Department of Neurophysiology and Experimental Epileptology, IRCCS Neurological Institute “Carlo Besta” Foundation, Milan, Italy
24 shared publications- Emilio Perucca
Department of Medicine (Austin Health) University of Melbourne Melbourne Victoria Australia
14 shared publications - Jakob Christensen
Department of Clinical Medicine Aarhus University Aarhus Denmark
11 shared publications - Julie Werenberg Dreier
National Centre for Register-based Research, Department of Public Health, Aarhus University, Aarhus, Denmark
10 shared publications - Piero Perucca
Department of Medicine (Austin Health) The University of Melbourne Melbourne Victoria Australia
10 shared publications Emilio Perucca
8 shared publications
Latest Publications
- 8 December 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (11)
Clinical Risk Factors for Suicide in Persons With Epilepsy
- 8 December 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (11)
Clinical Risk Factors for Suicide in Persons With Epilepsy
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7)
Gestational Changes in Antiseizure Medication Concentrations and the Impact of Polytherapy
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (7)
Gestational Changes in Antiseizure Medication Concentrations and the Impact of Polytherapy
- Open Access
Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVIII ). I. Treatments in preclinical and early clinical development
Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3–6, 2026. This article provides summaries of eight treatments in preclinical and early clinical development that were presented at EILAT XVIII. These include AUT00206, a positive allosteric modulator of Kv3.1 and Kv3.2 voltage‐gated potassium channels in development for the treatment of rare epilepsy syndromes as well as neurodevelopmental and neuropsychiatric disorders; ION283, an antisense oligonucleotide designed to suppress the expression of glycogen synthase 1, under investigation for the treatment of Lafora disease; MSCA‐7136, a selective allosteric RAS/mitogen‐activated protein kinase—extracellular signal regulated kinase (MEK) inhibitor being developed for the treatment of focal seizures associated with mesial temporal lobe epilepsy and seizures associated with tuberous sclerosis complex; OV329, a selective inhibitor of γ‐aminobutyric acid (GABA) aminotransferase, in development for the treatment of drug‐resistant focal seizures; PTI5803 (probenecid), an uricosuric agent and a blocker of pannexin 1 channels, repurposed as a treatment for seizures associated with focal cortical dysplasia; simufilam, a filamin A modulator under investigation for the treatment of tuberous sclerosis complex‐related epilepsy; SN‐2000, a selective allosteric phosphodiesterase 4B inhibitor, in development for the treatment of focal seizures; and sodium selenate, a promoter of the dephosphorylation of pathological hyperphosphorylated tau in the brain, under investigation as a disease‐modifying agent in mesial temporal lobe epilepsy. Treatments in more advanced clinical development are discussed in an accompanying article.
Open AccessProgress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVIII ). I. Treatments in preclinical and early clinical development
Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3–6, 2026. This article provides summaries of eight treatments in preclinical and early clinical development that were presented at EILAT XVIII. These include AUT00206, a positive allosteric modulator of Kv3.1 and Kv3.2 voltage‐gated potassium channels in development for the treatment of rare epilepsy syndromes as well as neurodevelopmental and neuropsychiatric disorders; ION283, an antisense oligonucleotide designed to suppress the expression of glycogen synthase 1, under investigation for the treatment of Lafora disease; MSCA‐7136, a selective allosteric RAS/mitogen‐activated protein kinase—extracellular signal regulated kinase (MEK) inhibitor being developed for the treatment of focal seizures associated with mesial temporal lobe epilepsy and seizures associated with tuberous sclerosis complex; OV329, a selective inhibitor of γ‐aminobutyric acid (GABA) aminotransferase, in development for the treatment of drug‐resistant focal seizures; PTI5803 (probenecid), an uricosuric agent and a blocker of pannexin 1 channels, repurposed as a treatment for seizures associated with focal cortical dysplasia; simufilam, a filamin A modulator under investigation for the treatment of tuberous sclerosis complex‐related epilepsy; SN‐2000, a selective allosteric phosphodiesterase 4B inhibitor, in development for the treatment of focal seizures; and sodium selenate, a promoter of the dephosphorylation of pathological hyperphosphorylated tau in the brain, under investigation as a disease‐modifying agent in mesial temporal lobe epilepsy. Treatments in more advanced clinical development are discussed in an accompanying article.
- Open Access
Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVIII ). II . Treatments in more advanced clinical development
This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026. The treatments reviewed include bexicaserin, a selective 5‐hydroxytryptamine (5‐HT, serotonin) type 2C (5‐HT 2C ) receptor superagonist investigated as a treatment for developmental and epileptic encephalopathies (DEEs); BMB‐101, a selective 5‐HT 2C receptor agonist investigated for the treatment of absence seizures and DEEs; elsunersen, an antisense oligonucleotide designed for the treatment of early‐onset SCN2A ‐DEE; EPX‐100 (clemizole hydrochloride), an antihistamine endowed with agonist activity at 5‐HT 2A and 5‐HT 2B receptors, repurposed as a treatment for DEEs; ES‐481, an antagonist of α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptors containing the transmembrane AMPA receptor regulatory protein γ8 (TARP‐γ8), under investigation for the treatment of drug‐resistant epilepsy; ETX‐101, a gene therapy in development for the treatment of SCN1A ‐positive Dravet syndrome; PrevEp‐006 (intranasal seletracetam), a synaptic vesicle glycoprotein 2A (SV2A) ligand under investigation as an acute seizure rescue therapy; radiprodil, a negative allosteric modulator that binds to the GluN2B subunit of the N ‐methyl‐ D ‐aspartate (NMDA) receptor, in development for the treatment of seizures and other symptoms associated with GRIN‐related neurodevelopmental disorder, tuberous sclerosis complex, and focal cortical dysplasia type II; RAP‐219, a selective negative allosteric modulator of TARP‐γ8, in development for drug‐resistant focal epilepsy; relutrigine, a selective disease‐state sodium channel modulator investigated as a treatment for SCN2A ‐ and SCN8A ‐DEE; Staccato Alprazolam, a breath‐actuated device that delivers alprazolam to the lungs for rapid seizure termination; vormatrigine, a functionally selective sodium channel modulator in development for the treatment of focal seizures; and zorevunersen, an antisense oligonucleotide engineered to restore endogenous Nav1.1 protein expression, investigated for the treatment of Dravet syndrome. Overall, the evidence reviewed justifies expectations for improved health outcomes for the millions of children and adults with epilepsy who do not fully benefit from existing therapies.
Open AccessProgress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVIII ). II . Treatments in more advanced clinical development
This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026. The treatments reviewed include bexicaserin, a selective 5‐hydroxytryptamine (5‐HT, serotonin) type 2C (5‐HT 2C ) receptor superagonist investigated as a treatment for developmental and epileptic encephalopathies (DEEs); BMB‐101, a selective 5‐HT 2C receptor agonist investigated for the treatment of absence seizures and DEEs; elsunersen, an antisense oligonucleotide designed for the treatment of early‐onset SCN2A ‐DEE; EPX‐100 (clemizole hydrochloride), an antihistamine endowed with agonist activity at 5‐HT 2A and 5‐HT 2B receptors, repurposed as a treatment for DEEs; ES‐481, an antagonist of α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptors containing the transmembrane AMPA receptor regulatory protein γ8 (TARP‐γ8), under investigation for the treatment of drug‐resistant epilepsy; ETX‐101, a gene therapy in development for the treatment of SCN1A ‐positive Dravet syndrome; PrevEp‐006 (intranasal seletracetam), a synaptic vesicle glycoprotein 2A (SV2A) ligand under investigation as an acute seizure rescue therapy; radiprodil, a negative allosteric modulator that binds to the GluN2B subunit of the N ‐methyl‐ D ‐aspartate (NMDA) receptor, in development for the treatment of seizures and other symptoms associated with GRIN‐related neurodevelopmental disorder, tuberous sclerosis complex, and focal cortical dysplasia type II; RAP‐219, a selective negative allosteric modulator of TARP‐γ8, in development for drug‐resistant focal epilepsy; relutrigine, a selective disease‐state sodium channel modulator investigated as a treatment for SCN2A ‐ and SCN8A ‐DEE; Staccato Alprazolam, a breath‐actuated device that delivers alprazolam to the lungs for rapid seizure termination; vormatrigine, a functionally selective sodium channel modulator in development for the treatment of focal seizures; and zorevunersen, an antisense oligonucleotide engineered to restore endogenous Nav1.1 protein expression, investigated for the treatment of Dravet syndrome. Overall, the evidence reviewed justifies expectations for improved health outcomes for the millions of children and adults with epilepsy who do not fully benefit from existing therapies.
- Top Cited PapersOpen Access
- 4 March 2026
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
Risk of neurodevelopmental disorders associated with paternal use of valproate during spermatogenesis
Background Regulatory authorities have raised concerns about potential teratogenic and neurodevelopmental disorders (NDDs) risks associated with paternal valproate use during spermatogenesis, leading to restrictions. We aimed to investigate the association between paternal valproate exposure during spermatogenesis and the risk of NDDs in offspring in Sweden and Norway. Methods We conducted a population-based cohort study of two nationwide cohorts from Sweden and Norway, including all singleton live births (≥22 gestational weeks) from 2007 to 2020. Paternal monotherapy exposure to valproate, lamotrigine or levetiracetam was defined as ≥1 prescription filled for only one of these medications during the 3 months prior to conception. NDDs were identified from health registers from age 1 through 2022. Cox proportional hazards models were used to estimate adjusted HRs (aHRs), accounting for relevant confounders. A random-effects meta-analysis combined results from both countries. Results The Swedish cohort included 1588 children with paternal valproate and 3093 with lamotrigine/levetiracetam monotherapy, while the Norwegian cohort included 463 and 1109, respectively. Compared with paternal lamotrigine/levetiracetam monotherapy, paternal valproate exposure was not associated with increased pooled risk of any NDD (aHR, 1.06; 95% CI 0.81 to 1.22), including autism spectrum disorder (aHR, 1.29; 95% CI 0.89 to 1.85), attention-deficit/hyperactivity disorder (aHR, 0.98; 95% CI 0.76 to 1.25), intellectual disability (aHR, 1.20; 95% CI 0.65 to 2.21; Sweden only) or psychological development disorders (aHR, 1.28; 95% CI 0.84 to 1.97). Findings remained consistent in dose–response analyses and when restricted to fathers with epilepsy. Conclusions In this large Nordic study, paternal valproate use during spermatogenesis was not associated with increased risk of NDDs in offspring, suggesting current regulatory restrictions may warrant re-evaluation.
- 4 March 2026
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
Top Cited PapersOpen AccessRisk of neurodevelopmental disorders associated with paternal use of valproate during spermatogenesis
Background Regulatory authorities have raised concerns about potential teratogenic and neurodevelopmental disorders (NDDs) risks associated with paternal valproate use during spermatogenesis, leading to restrictions. We aimed to investigate the association between paternal valproate exposure during spermatogenesis and the risk of NDDs in offspring in Sweden and Norway. Methods We conducted a population-based cohort study of two nationwide cohorts from Sweden and Norway, including all singleton live births (≥22 gestational weeks) from 2007 to 2020. Paternal monotherapy exposure to valproate, lamotrigine or levetiracetam was defined as ≥1 prescription filled for only one of these medications during the 3 months prior to conception. NDDs were identified from health registers from age 1 through 2022. Cox proportional hazards models were used to estimate adjusted HRs (aHRs), accounting for relevant confounders. A random-effects meta-analysis combined results from both countries. Results The Swedish cohort included 1588 children with paternal valproate and 3093 with lamotrigine/levetiracetam monotherapy, while the Norwegian cohort included 463 and 1109, respectively. Compared with paternal lamotrigine/levetiracetam monotherapy, paternal valproate exposure was not associated with increased pooled risk of any NDD (aHR, 1.06; 95% CI 0.81 to 1.22), including autism spectrum disorder (aHR, 1.29; 95% CI 0.89 to 1.85), attention-deficit/hyperactivity disorder (aHR, 0.98; 95% CI 0.76 to 1.25), intellectual disability (aHR, 1.20; 95% CI 0.65 to 2.21; Sweden only) or psychological development disorders (aHR, 1.28; 95% CI 0.84 to 1.97). Findings remained consistent in dose–response analyses and when restricted to fathers with epilepsy. Conclusions In this large Nordic study, paternal valproate use during spermatogenesis was not associated with increased risk of NDDs in offspring, suggesting current regulatory restrictions may warrant re-evaluation.
- 10 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (3) , e214570
Transcription Factor Binding and Individual Genetic Risk of Valproate Teratogenicity
Valproate (VPA) use during pregnancy is associated with a wide range of structural birth defects, but not all exposed children are affected and there is evidence for a genetic predisposition. The development of a pharmacogenomic biomarker test that can be used for preconception counseling, allowing access to women unnecessarily denied VPA treatment because of concern about teratogenic risks if they were to become pregnant, is challenged by a poor understanding of how variation in maternal DNA could modify the risk. We hypothesized that genomic variants that affect the binding affinity of transcription factors (TFs), key regulators of gene expression, are integral to VPA-associated teratogenicity and a plausible explanation for both variance in interindividual risk and the wide range of birth defect types. We interrogated genomic variants within maternal exomes from women recruited through international epilepsy pregnancy registries and genomics consortia. We applied a network-based approach that contextualized the variant spectra to genes associated with diverse birth defect types, gene burden tests, and evidence from multiple modalities to identify variant-sensitive TFs. Sixty-six pregnancies were exposed to VPA as monotherapy or polytherapy, leading to 28 cases with birth defects, and 184 were exposed to other antiseizure medications (ASMs), leading to 20 cases with birth defects. The variant burden within genes associated with 32 different birth defect types was higher for those exposed to VPA compared with those exposed to other ASMs (OR 1.73 [95% CI 1.39 to 2.13], p < 0.0001). Variants in a network comprising significant genes from VPA-exposed mothers were predicted to modify the binding affinity of 359 TFs. These variant-sensitive TFs formed a highly connected protein-protein interaction network, among which the acetyltransferase EP300 connected to 41% (147/359) of all proteins. Profiling of coexpression between EP300 and other TFs in an embryonic stem cell (hESC) model showed that VPA exposure alters EP300-TF interactions. These findings suggest that VPA-induced disruption of EP300-related gene regulation is a teratogenic mechanism that is common to heterogeneous birth defect types and sensitive to genetic variation. This has implications for the development of pharmacogenomic risk biomarkers and safer drugs for women of childbearing potential.
- 10 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (3) , e214570
Transcription Factor Binding and Individual Genetic Risk of Valproate Teratogenicity
Valproate (VPA) use during pregnancy is associated with a wide range of structural birth defects, but not all exposed children are affected and there is evidence for a genetic predisposition. The development of a pharmacogenomic biomarker test that can be used for preconception counseling, allowing access to women unnecessarily denied VPA treatment because of concern about teratogenic risks if they were to become pregnant, is challenged by a poor understanding of how variation in maternal DNA could modify the risk. We hypothesized that genomic variants that affect the binding affinity of transcription factors (TFs), key regulators of gene expression, are integral to VPA-associated teratogenicity and a plausible explanation for both variance in interindividual risk and the wide range of birth defect types. We interrogated genomic variants within maternal exomes from women recruited through international epilepsy pregnancy registries and genomics consortia. We applied a network-based approach that contextualized the variant spectra to genes associated with diverse birth defect types, gene burden tests, and evidence from multiple modalities to identify variant-sensitive TFs. Sixty-six pregnancies were exposed to VPA as monotherapy or polytherapy, leading to 28 cases with birth defects, and 184 were exposed to other antiseizure medications (ASMs), leading to 20 cases with birth defects. The variant burden within genes associated with 32 different birth defect types was higher for those exposed to VPA compared with those exposed to other ASMs (OR 1.73 [95% CI 1.39 to 2.13], p < 0.0001). Variants in a network comprising significant genes from VPA-exposed mothers were predicted to modify the binding affinity of 359 TFs. These variant-sensitive TFs formed a highly connected protein-protein interaction network, among which the acetyltransferase EP300 connected to 41% (147/359) of all proteins. Profiling of coexpression between EP300 and other TFs in an embryonic stem cell (hESC) model showed that VPA exposure alters EP300-TF interactions. These findings suggest that VPA-induced disruption of EP300-related gene regulation is a teratogenic mechanism that is common to heterogeneous birth defect types and sensitive to genetic variation. This has implications for the development of pharmacogenomic risk biomarkers and safer drugs for women of childbearing potential.
- 3 September 2025
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 21 (10) , 1151-1158
Paternal exposure to antiseizure medications and offspring outcomes: a systematic review and meta-analysis of observational studies
To assess the risk of adverse offspring outcomes related to paternal antiseizure treatment during conception. We identified studies of offspring outcomes for fathers with vs. without antiseizure medication(s) during conception in Embase/Medline in 01/2025. Study quality was evaluated using the Newcastle-Ottawa-Scale. Our primary outcome was the odds ratio (OR, 95% confidence intervals [95%CI]) of offspring outcomes in fathers with vs. without antiseizure medication(s). A subgroup analysis assessing the study design impact and sensitivity analyses after excluding poor-quality studies, and sequentially each study, were performed. Of the six studies included (k = 6, n = 17,974), two and four were rated as good- and poor-quality studies, respectively. There were no differences regarding risk of major congenital malformations in offsprings with vs. without paternal antiseizure medication(s) (OR = 1.22, 95%CI = 0.55 to 2.68, p = 0.63), with substantial heterogeneity (I2 = 93.0%). In six studies (k = 6, n = 17,604) there were no differences regarding risk of neurodevelopmental disorders in offsprings with vs. without paternal antiseizure medication(s) (OR = 1.21, 95%CI = 0.73 to 1.99, p = 0.46, I2 = 95.6%); ORs of paternal antiseizure medication-related neurodevelopmental disorders were higher in cross-sectional (n = 3) vs. cohort studies (n = 3) (p < 0.001). There is no evidence of elevated risk of adverse outcomes for offsprings with vs. without paternal antiseizure treatment, although heterogeneity was substantial. www.crd.york.ac.uk/prospero identifier is CRD42025635478.
- 3 September 2025
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 21 (10) , 1151-1158
Paternal exposure to antiseizure medications and offspring outcomes: a systematic review and meta-analysis of observational studies
To assess the risk of adverse offspring outcomes related to paternal antiseizure treatment during conception. We identified studies of offspring outcomes for fathers with vs. without antiseizure medication(s) during conception in Embase/Medline in 01/2025. Study quality was evaluated using the Newcastle-Ottawa-Scale. Our primary outcome was the odds ratio (OR, 95% confidence intervals [95%CI]) of offspring outcomes in fathers with vs. without antiseizure medication(s). A subgroup analysis assessing the study design impact and sensitivity analyses after excluding poor-quality studies, and sequentially each study, were performed. Of the six studies included (k = 6, n = 17,974), two and four were rated as good- and poor-quality studies, respectively. There were no differences regarding risk of major congenital malformations in offsprings with vs. without paternal antiseizure medication(s) (OR = 1.22, 95%CI = 0.55 to 2.68, p = 0.63), with substantial heterogeneity (I2 = 93.0%). In six studies (k = 6, n = 17,604) there were no differences regarding risk of neurodevelopmental disorders in offsprings with vs. without paternal antiseizure medication(s) (OR = 1.21, 95%CI = 0.73 to 1.99, p = 0.46, I2 = 95.6%); ORs of paternal antiseizure medication-related neurodevelopmental disorders were higher in cross-sectional (n = 3) vs. cohort studies (n = 3) (p < 0.001). There is no evidence of elevated risk of adverse outcomes for offsprings with vs. without paternal antiseizure treatment, although heterogeneity was substantial. www.crd.york.ac.uk/prospero identifier is CRD42025635478.
- Open Access
Treatment of epilepsy using newer antiseizure medications: A retrospective cohort study of prescription patterns in Sweden 2013–2022
Objective: This study aimed to analyze the choice of newly introduced antiseizure medications (ASMs; brivaracetam, cannabidiol, cenobamate, fenfluramine, and perampanel) by age and sex, and the use of these ASMs in relation to regulatory approval. Methods: Patients were identified with dispensation of any ASM subsequent to at least one health care contact due to epilepsy (International Classification of Diseases, 10th Revision: G40) during 2000–2022. Incidence rate ratios (IRRs) for starting a newly introduced ASM, retention rates, number of ASM treatments preceding the first dispensation of a new ASM and concurrent ASM treatments at first dispensed new ASM, and share of patients using new ASMs as adjunctive treatment were calculated. Results: Three percent of all patients identified with epilepsy treatment during the period 2013–2022 used at least one new ASM. IRRs for ever being dispensed a new ASM differed between age groups for all ASMs except cenobamate. The corresponding IRRs associated with sex were insignificantly different from 1, except for cannabidiol; men were more likely to start using cannabidiol. One‐year retention rates were between 42% (cannabidiol, men) and 64% (brivaracetam, men). The majority (70%) of patients had used >2 ASMs prior to the first dispensation of a new ASM, and a majority (98%) of patients were treated with another ASM at first dispensation of a new ASM (≤90 days before). Similarly, 82% of the patients who started using a new ASM did so as an adjunctive treatment (ASMs dispensed ≤90 days before and ≥90 days after first new ASM). Significance: Our observations indicate that prescription patterns of the newer ASMs comply with the currently approved indications for the respective medications for a majority of patients (prevalence of brivaracetam as adjunctive treatment is somewhat lower). Retention on the dispensed medications are in line with what would be expected for adjunctive treatment of patients with drug‐resistant epilepsies.
Open AccessTreatment of epilepsy using newer antiseizure medications: A retrospective cohort study of prescription patterns in Sweden 2013–2022
Objective: This study aimed to analyze the choice of newly introduced antiseizure medications (ASMs; brivaracetam, cannabidiol, cenobamate, fenfluramine, and perampanel) by age and sex, and the use of these ASMs in relation to regulatory approval. Methods: Patients were identified with dispensation of any ASM subsequent to at least one health care contact due to epilepsy (International Classification of Diseases, 10th Revision: G40) during 2000–2022. Incidence rate ratios (IRRs) for starting a newly introduced ASM, retention rates, number of ASM treatments preceding the first dispensation of a new ASM and concurrent ASM treatments at first dispensed new ASM, and share of patients using new ASMs as adjunctive treatment were calculated. Results: Three percent of all patients identified with epilepsy treatment during the period 2013–2022 used at least one new ASM. IRRs for ever being dispensed a new ASM differed between age groups for all ASMs except cenobamate. The corresponding IRRs associated with sex were insignificantly different from 1, except for cannabidiol; men were more likely to start using cannabidiol. One‐year retention rates were between 42% (cannabidiol, men) and 64% (brivaracetam, men). The majority (70%) of patients had used >2 ASMs prior to the first dispensation of a new ASM, and a majority (98%) of patients were treated with another ASM at first dispensation of a new ASM (≤90 days before). Similarly, 82% of the patients who started using a new ASM did so as an adjunctive treatment (ASMs dispensed ≤90 days before and ≥90 days after first new ASM). Significance: Our observations indicate that prescription patterns of the newer ASMs comply with the currently approved indications for the respective medications for a majority of patients (prevalence of brivaracetam as adjunctive treatment is somewhat lower). Retention on the dispensed medications are in line with what would be expected for adjunctive treatment of patients with drug‐resistant epilepsies.
- 11 March 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (5) , e213372
Influence of Risk Factor Combinations on Incidence Rates of SUDEP
Information on absolute risks of sudden unexpected death in epilepsy (SUDEP) in individual patients with epilepsy is scarce. Our main objective was therefore to explore the range in incidence rates of SUDEP to provide a more solid basis for individualized counseling and to characterize patients with high and very high SUDEP incidence for future intervention studies aiming at prevention of SUDEP. We used data on everyone in Sweden diagnosed with epilepsy from 1998 to 2005 (n = 60,952), followed until 2011 and identified SUDEP cases through adjudication of deceased patients who had epilepsy. We conducted a nested case-control study and retrieved detailed information on clinical characteristics for the SUDEP cases and matched living epilepsy controls (5:1). Estimates of the strengths of associations from the case-control study were used to estimate the incidence rate of SUDEP (per 100,000 person-years) in the full cohort by SUDEP risk factors. Two hundred fifty-five SUDEP cases (median age 48 years; 154 males) were identified. The lowest incidence, 8 (95% CI 3-17), was observed among patients without a history of tonic-clonic seizures (TCS), whereas patients with 1 or more TCS the preceding year had an incidence of 287 (95% CI 192-428). Incidence rates above 200 were also found among patients with a history of nocturnal TCS, substance abuse or alcohol dependence, and nonadherence with antiseizure medication (ASM) treatment. Considering combination of risk factors, the incidence rate was very low, 5 (95% CI 2-12), for patients who share bedroom and are free from TCS the preceding year as well as adherent with the prescribed ASM treatment. By contrast, patients living alone who are nonadherent have a history of nocturnal TCS and at least 1 TCS the preceding year have an incidence at 1808 (95% CI 594-5,504), more than 350 times higher than the low-risk patient. In this analysis of Swedish population-based SUDEP data, we have identified a 350-fold difference in the SUDEP incidence depending on individual circumstances and epilepsy characteristics. Although somewhat old, our data should be useful for patient counseling about individual SUDEP risks amenable to modification and for case stratifications for intervention studies aiming at prevention of SUDEP.
- 11 March 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (5) , e213372
Influence of Risk Factor Combinations on Incidence Rates of SUDEP
Information on absolute risks of sudden unexpected death in epilepsy (SUDEP) in individual patients with epilepsy is scarce. Our main objective was therefore to explore the range in incidence rates of SUDEP to provide a more solid basis for individualized counseling and to characterize patients with high and very high SUDEP incidence for future intervention studies aiming at prevention of SUDEP. We used data on everyone in Sweden diagnosed with epilepsy from 1998 to 2005 (n = 60,952), followed until 2011 and identified SUDEP cases through adjudication of deceased patients who had epilepsy. We conducted a nested case-control study and retrieved detailed information on clinical characteristics for the SUDEP cases and matched living epilepsy controls (5:1). Estimates of the strengths of associations from the case-control study were used to estimate the incidence rate of SUDEP (per 100,000 person-years) in the full cohort by SUDEP risk factors. Two hundred fifty-five SUDEP cases (median age 48 years; 154 males) were identified. The lowest incidence, 8 (95% CI 3-17), was observed among patients without a history of tonic-clonic seizures (TCS), whereas patients with 1 or more TCS the preceding year had an incidence of 287 (95% CI 192-428). Incidence rates above 200 were also found among patients with a history of nocturnal TCS, substance abuse or alcohol dependence, and nonadherence with antiseizure medication (ASM) treatment. Considering combination of risk factors, the incidence rate was very low, 5 (95% CI 2-12), for patients who share bedroom and are free from TCS the preceding year as well as adherent with the prescribed ASM treatment. By contrast, patients living alone who are nonadherent have a history of nocturnal TCS and at least 1 TCS the preceding year have an incidence at 1808 (95% CI 594-5,504), more than 350 times higher than the low-risk patient. In this analysis of Swedish population-based SUDEP data, we have identified a 350-fold difference in the SUDEP incidence depending on individual circumstances and epilepsy characteristics. Although somewhat old, our data should be useful for patient counseling about individual SUDEP risks amenable to modification and for case stratifications for intervention studies aiming at prevention of SUDEP.